Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. April 2016 06:50 ET | Quelle: Insys Therapeutics, Inc.

Insys Therapeutics Reports Preliminary Estimated Revenues from Subsys for the First Quarter 2016

PHOENIX, April 11, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that its preliminary estimated revenues from Subsys® (fentanyl...
22. März 2016 16:05 ET | Quelle: Insys Therapeutics, Inc.

Insys Therapeutics, Inc. Announces 3-Month Extension of PDUFA Date for Syndros

PHOENIX, March 22, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act...
10. März 2016 10:21 ET | Quelle: Insys Therapeutics, Inc.

USPTO Declines to Institute All Inter Partes Review Petitions Filed by CFAD of Insys U.S. Patents Directed to SUBSYS (fentanyl sublingual spray)

PHOENIX, March 10, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that the Patent Trial and Appeal Board (PTAB) of the United States...
23. Februar 2016 06:50 ET | Quelle: Insys Therapeutics, Inc.

Insys Therapeutics Reports Fourth Quarter and Year End 2015 Results

PHOENIX, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced financial results for the three- and twelve-month periods ended...
10. Februar 2016 06:50 ET | Quelle: Insys Therapeutics, Inc.

Insys Therapeutics, Inc. to Present at RBC Capital Markets 2016 Global Healthcare Conference

PHOENIX, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Chief Medical Officer, and Darryl...
09. Februar 2016 06:50 ET | Quelle: Insys Therapeutics, Inc.

Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD

PHOENIX, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that the Company has enrolled the first patient in a Phase II clinical...
03. Februar 2016 16:30 ET | Quelle: Insys Therapeutics, Inc.

Insys Therapeutics to Report Fourth Quarter and Full Year 2015 Results

PHOENIX, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its financial results for the fourth quarter...
25. Januar 2016 12:54 ET | Quelle: Insys Therapeutics, Inc.

Insys Therapeutics Releases Statement on Its Patient Services Center

PHOENIX, Jan. 25, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq:INSY) (“Insys” or “the Company”) today issued the following statement in response to misleading reports in the media...
30. Dezember 2015 07:00 ET | Quelle: Insys Therapeutics, Inc.

Insys Therapeutics, Inc. to Present at J.P. Morgan 34th Annual Healthcare Conference

PHOENIX, Dec. 30, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Dan Brennan, Chief Operating Officer, and Darryl Baker, Chief...
04. Dezember 2015 07:00 ET | Quelle: Insys Therapeutics, Inc.

Insys Therapeutics Responds to False and Misleading Report

PHOENIX, Dec. 04, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq:INSY) (“Insys” or “the Company”) today issued the following response to a recent report containing accusations centered...

Vorherige Seite